Loss of constitutive heterozygosity at 11q23 has been detected in various human solid tumors. Here, we described the analysis of a series of normal and tumor pairs from 110 breast carcinomas for the presence of loss of heterozygosity at 11q23 loci. The overall frequency of LOH was 48%, con®rming the importance of deletions at 11q23 in breast tumorigenesis. Previously, we have identi®ed two independent regions of LOH at 11q23, the LOH region 1 at 11q23.1 and the LOH region 2 at 11q23.3. The most telomeric region was recently re®ned between loci D11S1345 and D11S1316, a region of about 1 Mb. However, the LOH region 1, most centromeric, was still not ®nely re®ned: the boundaries were de®ned by loci D11S2000 and D11S897, separated by about 8 Mb. Here, we re®ned its boundaries between loci D11S1347 and D11S927, a region of about 2 Mb. We have mapped 11 expressed sequence tags (ESTs) within this region and excluded another 20. This study represents a further step toward the identi®cation of the putative tumor suppressor gene found within the LOH region 1 at 11q23.1.
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Keywords: LOH at 11q23; breast cancer Loss of heterozygosity studies are believed to pinpoint the location of cancer recessive genes, and several studies have indicated that the long arm of chromosome 11 harbors genes that are deleted during tumorigenesis. Deletions at 11q23 were detected in a variety of human neoplasms, including breast (Carter et al., 1994; Hampton et al., 1994a; Kerangueven et al., 1997; Laake et al., 1997; Negrini et al., 1995) , lung (Iizuka et al., 1995; Rasio et al., 1995) , cervical (Bethwaite et al., 1995; Hampton et al., 1994b; Srivatsan et al., 1991) , ovarian (Davis et al., 1996; Foulkes et al., 1993; Gabra et al., 1996) , prostate (Dahiya et al., 1997) , colorectal (Gustafson et al., 1994; Keldysh et al., 1993) , nasopharyngeal carcinomas , melanoma (Herbst et al., 1995; Tomlinson et al., 1993) and rhabdomyosarcoma (Visser et al., 1997) . These results strongly suggested that region 11q23 harbors at least one tumor suppressor gene, which is inactivated during the establishment or progression of these types of tumors. Whether the same gene is involved in all of them is not established.
Toward the identi®cation of the critical tumor suppressor genes at 11q23, re®nement of the minimal regions of LOH resulted in the identi®cation of at least two independent regions of deletion in breast carcinomas : the LOH region 1, de®ned between loci D11S2000 and D11S897, with an estimated size of about 8 Mb, and the LOH region 2, between loci D11S1345 and D11S1316 (Monaco et al., 1997) , whose estimated size is about 1 Mb. Similar re®ned regions of deletion were identi®ed also in lung and ovarian carcinomas (Davis et al., 1996) .
The ATM gene, located within the LOH region 1, was a strong candidate tumor suppressor gene, since aected AT patients have a predisposition to malignancy, mainly B-cell lymphomas and T-cell leukemias, suggesting that loss of ATM functions could be involved in tumor development. Supporting the concept that ATM may act as a tumor susceptibility gene was the ®nding that inactivation of both copies of the ATM gene is involved in the pathogenesis of sporadic T cell leukemias (Stilgenbauer et al., 1997; Vorechovsky et al., 1997) . Swift et al. (1991) estimated that, for AT heterozygote carriers, the relative risk of cancer was 2.3 for men and 3.1 for women, with breast cancer being the most clearly associated neoplasia with heterozygosity for AT, estimating that as much as 8% of sporadic breast cancer could possibly develop in carriers of ATM gene predisposing mutations (Swift et al., 1991) . However, our studies in sporadic breast cancer indicated that ATM is not the critical tumor suppressor gene at 11q23 and its role in familial predisposition is still controversial (Fitzgerald et al., 1997; Vorechovsky et al., 1996a,b) .
In addition to LOH studies, cell biology studies indicated that region 11q13-q23, containing the LOH region 1 but not the LOH region 2, can partially suppress tumorigenicity of cells from the breast cancer cell line MCF-7 , con®rming the existence of a gene that control tumorigenicity within this chromosomal region. Results indicating the existence of a tumor suppressor gene on the long arm of chromosome 11 was also reported for the rhabdomyosarcoma cell line RD (Loh et al., 1992 ).
It appears therefore that a tumor suppressor gene close but distinct from the ATM gene exists within the LOH region 1. In this report, we have re®ned the region of deletion and, based on the reported transcriptional map of the human genome, we have re®ned the mapping of expressed sequence tags (ESTs), that should help to identify the critical tumor suppressor gene of the region.
Paired normal and tumor DNAs from 110 breast carcinomas were analysed using polymorphic microsatellite markers from chromosome 11q23. All breast tumor samples were malignant carcinomas, histopathologically identi®ed and classi®ed. All histotypes were represented. Ten markers (D11S2000, D11S2179, D11S1778, D11S1294, D11S1818, D11S927, D11S1300, D11S1391, D11S1893, D11S1347) were used to search for LOH in the previously described LOH region 1 , three markers (D11S1345, D11S1284, D11S1328) were used to analyse the LOH region 2 (Monaco et al., 1997) and one marker (D11S29) was between the two regions. Oligonucletide primers and PCR conditions were as previously described or obtained from the Genome Database at the Internet address http://gbdwww.gdb.org. Overall, the frequency of LOH detected at 11q23 at at least one locus was 48% (53/ 111), with the highest frequencies detected for loci D11S1391 (39%: 31 out of 79 informative cases) within the LOH region 1 and D11S1345 (37%: 28 out of 76 informative cases) at the LOH region 2. LOH was initially scored by visual inspection. Then, microsatellites were analysed by densitometric scanning as previously reported and LOH was con®rmed when the ratio between alleles in tumor DNA diered more than 30% from the ratio detected in the paired normal DNA. At least 20 samples showed discordant LOH between the region 1 at 11q23.1 and the region 2 at 11q23.3. These results con®rmed the critical role of genes at 11q23 in breast tumorigenesis as indicated by the high frequency of LOH at 11q23 and the presence of at least two independent regions of deletion.
Clinico-pathological data, including age, tumor histotype, tumor stage, lymph node and distant metastasis, estrogen receptor status, were obtained for all the samples. We did not ®nd any statistically signi®cant correlation between the above parameters and LOH at 11q23. Also association with familial history of breast or other neoplasms was not signi®cant. To date, correlation between LOH at 11q23 and clinico-pathological parameters has been only found with a poorer survival rate after metastasis (Winqvist et al., 1995) and with lack of progesterone receptor expression (Tomlinson et al., 1996) , associations that, however, need to be con®rmed by additional studies. Data concerning the progesterone receptor status and survival rate were not available for the samples we analysed in this study. Although these data are not conclusive, it seems that a strong correlation between LOH at 11q23 and the most commonly used clinico-pathological parameters do not exist in breast cancer. Lack of association between clinico-pathological parameters and LOH at 11q23 was also reported for prostate cancer (Dahiya et al., 1997) .
The analysis of the deletions detected in this series of 110 breast tumor samples revealed that the minimal region of deletion within the LOH region 1 could be re®ned between loci D11S927-D11S1347. The analysis of the deletions observed in tumor samples 48, 69 and 122 suggested this conclusion: in these three tumor samples the deletions are limited to the area between these two loci ( Figure 1) . As judged from the YAC contig of the region (Arai et al., 1996) , the size of the Figure 1 Tumor samples critical for the re®nement of the LOH region 1. Three tumor samples, No. 48, 69 and 122, showed a discrete deletion between loci D11S1347 and D11S927, which retained constitutive heterozygosity in tumor DNA, while loss of heterozygosity was detected at loci, D11S1300 or D11S1391, found within the interval. N and T denote normal and tumor DNA, respectively area is about 2 Mb, which is about one fourth the size of the previously identi®ed LOH region 1, de®ned by loci D11S2000-D11S897 . The re®nement of the LOH region 1 between D11S1347 and D11S927 con®rmed that the region most frequently deleted in breast cancer does not include the ATM gene, indicating that a dierent, but close, gene is involved in the pathogenesis of breast cancer. However, comparison with other recent studies (Laake et al., 1997) reveals that the region of LOH identi®ed in the present study, D11S1347-D11S927, and that identi®ed by Laake et al. are contiguous, but not overlapping. These apparently contradictory results may re¯ect a dierence in the analysed tumor samples and the existence of more than one tumor recessive gene in the region. The complexity of the deletions found at 11q23 is clearly shown by the study reported by Kerangueven et al. (1997) , that recognizes ®ve regions of loss at chromosomal bands 11q22-q24, three of them at the LOH region 1. Since the ATM gene can be excluded as being the critical tumor suppressor gene at 11q23 involved in sporadic breast cancer (Vorechovsky et al., 1996b) , judging from the various studies carried out in dierent laboratories, the minimal region where to search for a tumor suppressor gene is telomeric to ATM (D11S2179) but centromeric to D11S1347 and, possibly, the existence of more than one tumor suppressor gene within this region cannot be excluded.
The report of the human transcript map based on expressed sequence tag (EST) sequences provided the ®rst framework revealing the location of genes on the human chromosomes (Schuler et al., 1996) , Thirty-one ESTs (Table 1) , whose sub-chromosomal location was obtained from the Internet address http:// www.ncbi.nlm.gov/SCIENCE96/, were examined with the use a YAC contig spanning the same region. Twelve overlapping YACs were analysed by PCR using oligonucleotides speci®c for the 31 ESTs. Oligonucleotide primers information was obtained from the same Internet address. Results of the re®ned mapping of these ESTs are summarized in Figure 2 and Table 1 . Table 1 . Information about these ESTs, including nucleotide sequences and oligonucleotide primers, can be found at the following Internet addresses: http://www.ncbi.nlm.nih.gov/cgi-bin/SCIENCE96/chr?11 or http://gdbwww.gdb.org/ + + ± ± ± ± ± + ± + ± + ± ± ± ± ± ± ± ± + ± + + + + + ± ± ± ± + + + + + + ± + + + + + ± + + ± ± ± ± ± + ± + + + + + ± ± ± ± a The numbers correspond to those indicated in Figure 2. b Locus features and oligonucleotide primers identifying these ESTs can be found at the following internet page address: www.ncbi.nlm.nih.gov/ cgi-bin/SCIENCE96/chr?11
Based on these results, 11 ESTs map within the re®ned LOH region 1 D11S1347-D11S927, eight additional ESTs map within the old larger LOH region 1 D11S2000-D11S897 and the remaining 12 map outside this region. Analysis of the 11 ESTs with the region D11S1347-D11S927 revealed that the only known gene found within the region is that encoding for the ferredoxin-1 (FDX-1) . Once the critical regions of deletion are further reduced in size and better de®ned in the various neoplasms, the re®nement in the chromosomal localization of ESTs should help to identify and clone the critical tumor suppressor gene(s) of this region.
